Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
Key Information
Due Date: June 20, 2025
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: $581,371
Funding Type: Cooperative Agreement
Match Required: No
Contact Info:
grantsinfo@nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
A key phase supported by this grant is the initial proof of concept studies. These studies are intended to help identify measures that could possibly be used to develop preclinical assays. These assays would be used to evaluate the potential efficacy of new drug and device therapies and their specific targets.
Moreover, through the data gathered, discrepancies between the performances of preclinical animal species and humans can be identified. This information will establish a solid foundation for limiting speculative extrapolations from animal-based preclinical findings to humans, thereby increasing the accuracy and efficacy of research.
Ultimately, the practical aim of this grant is to create a more efficient therapeutic development process. By identifying measure consistencies and disparities between preclinical screenings and clinical evaluations of new treatment candidates, the grant intends to speed up the development of effective treatments for mental disorders.
Key Dates
Open Date: January 13, 2023
Application Due Date: June 20, 2025
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses